Table 2.

Clinical characteristics of the three cohort of patients.

Characteristics	Subgroup A	Subgroup B	Subgroup C
	n. 37 patients	n. 43 patients	n. 15 patients
Sex p-value: 0.785
Males	29 (78.4%)	35 (81.4%)	13 (86.7%)
Females	8 (21.6%)	8 (18.6%)	2 (13.3%)
Immunotherapy p-value: 0.818
Nivolumab	28 (75.7%)	31 (72.1%)	10 (66.7%)
Atezolizumab	9 (24.3%)	12 (27.9%)	5 (33.3%)
Histology p-value: 0.973
Squamous	12 (32.4%)	15 (34.9%)	5 (33.3%)
Non-squamous	25 (67.6%)	28 (65.15)	10 (66.7%)
IrAEs p-value: 0.465
Yes	13 (35.1%)	16 (37.2%)	3 (20%)
No	24 (64.9%)	27 (62.8%)	12 (80%)
Age p-value: 0.156
<50 years	1 (2.7%)	2 (4.7%)	2 (13.3%)
50–65 years	15 (40.5%)	17 (39.6%)	6 (40%)
65–75 years	13 (35.1%)	15 (34.8%)	6 (40%)
>75 years	8 (21.7%)	9 (20.9%)	1 (6.7%)
Expression of PD-L1 expression, categorized p-value: 0.818
<1%	6 (16.2%)	9 (20.9%)	4 (26.6%)
1–50%	11 (29.8%)	15 (34.9%)	4 (26.7%)
>50%	8 (21.6%)	6 (13.9%)	1 (6.7%)
Missing	12 (32.4%)	13 (30.3%)	6 (40%)

Subgroup A included 37 patients with baseline ESR values ≤40 mm/h and baseline PCT values ≤0.10 ng/L. Subgroup B included 43 patients’ baseline ESR values >40 mm/h or baseline PCT values >0.10 ng/L. Subgroup C included 15 patients with baseline ESR values >40 mm/h and baseline PCT values >0.10 ng/L. Chi-Square analysis showed no differences in clinical variables among the three groups.